MiMedx Group, Inc.

NASDAQ:MDXG

Biotechnology

Healthcare
$3.18 +2.22%

+$0.08 today

Market cap
$464.04M
Beta
1.46
P/E (TTM)
17.8
EPS (TTM)
$0.21
52W Low $3.03High $7.99

Volume 1.51M

Average 1.55M

MDXG Long-term Debt

Borrowings due after more than one year.

MiMedx Group, Inc.NASDAQ: MDXG

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt falls 8.2% from a year ago

Long-term debt stood at $16.09M at the end of Q1 FY2026, down 8.2% from a year earlier and down 2.3% from the prior quarter. Over 3 fiscal years it compounded at -30.3% a year.

Context

  • Long-term debt amounted to 5.2% of total assets at the end of Q1 FY2026, down 1.3 pp from a year earlier.
  • Long-term debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -8.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$16.09M-2.3% QoQ
Last fiscal yearDec 2025
$16.47M-7.6% YoY
Year agoMar 2025
$17.53M-8.2% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.2%——
1 year-7.6%——
3-year CAGR-30.3%——
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
16.47M USD
Year-over-year change
-7.6%
4-year CAGR
-23.5%

Long-term Debt vs competitors

How MDXG compares with its peers on the latest reported figures

  • MDXG's Mar 2026 long-term debt of $16.09M is the 2nd highest of the 8 companies compared; the peer median is $0.
  • Its year-over-year change of -8.2% is the 2nd highest of 5, against a peer median of -97.2%.
  • Long-term debt amounts to 5.2% of total assets for MDXG, versus a peer median of 0.0%.
MDXG Competitors Peer median
Long-term Debt for MDXG and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SMTISanara MedTech Inc.Mar 2026$46.23M +6.5%—66.7%
MDXGMiMedx Group, Inc.Mar 2026$16.09M -8.2%-30.3%5.2%
RCELAVITA Medical, Inc.Mar 2026$1.98M -95.2%—3.8%
BSEMBioStem Technologies, Inc.Jun 2026$1.36K -99.1%—0.0%
LCTXLineage Cell Therapeutics, Inc.Mar 2026$0 ——0.0%
MDWDMediWound Ltd.Mar 2026$0 ——0.0%
ORGOOrganogenesis Holdings Inc.Mar 2026$0 —-8.5%0.0%
CELUCelularity Inc.Dec 2025$0 -100.0%—0.0%
Peer median (excluding MDXG) $0-97.2%-8.5%0.0%

Competitors are the stored peer set for MDXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents87.08M65.95M82M104.42M166.12M
Short-term Investments00000
Net Receivables40.35M43.08M53.87M55.83M75.71M
Inventory11.39M13.18M21.02M23.81M25.34M
Other Current Assets3.55M4.67M1.75M2.82M10.3M
Total Current Assets148.52M134.2M164.26M191.89M277.47M
Property, Plant & Equipment (Net)13.86M11.26M9.11M11.55M4.71M
Goodwill19.98M19.44M19.44M19.44M19.44M
Intangible Assets5.38M5.85M5.26M11.63M14.16M
Long-term Investments00000
Tax Assets0040.78M28.31M19.6M
Other Non-current Assets186K683K205K1.11M7.27M
Total Non-current Assets39.41M37.23M74.79M72.03M65.18M
Total Assets187.93M171.43M239.05M263.92M342.65M
Account Payables7.39M8.45M9.05M7.41M14.53M
Short-term Debt01.44M01M2.82M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities3.91M12.81M14.61M25.45M15.85M
Total Current Liabilities42.36M43.56M46.01M45.6M64.27M
Long-term Debt48.13M48.59M48.1M17.83M16.47M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities951K2.34M2.22M2.68M2.13M
Total Non-current Liabilities53M53.37M50.32M25.21M21.84M
Total Liabilities95.35M96.92M96.33M70.81M86.11M
Common Stock113K114K146K147K148K
Retained Earnings(161.71M)(191.91M)(133.68M)(91.26M)(42.68M)
Accumulated OCI00000
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity92.58M74.51M142.72M193.11M256.55M
Total Debt53.29M52.47M48.1M24.84M22.53M
Net Debt(33.79M)(13.48M)(33.9M)(79.57M)(143.59M)

MiMedx Group, Inc.

NASDAQ:MDXG

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.